Home » Stocks » OGEN

Oragenics Inc. (OGEN)

Stock Price: $0.929 USD -0.021 (-2.24%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
Market Cap 86.01M
Revenue (ttm) n/a
Net Income (ttm) -25.62M
Shares Out 59.67M
EPS (ttm) -0.50
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $0.929
Previous Close $0.950
Change ($) -0.021
Change (%) -2.24%
Day's Open 0.955
Day's Range 0.902 - 1.030
Day's Volume 30,380,465
52-Week Range 0.386 - 1.490

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
InvestorPlace - 2 days ago

Oragenics (OGEN) stock is soaring higher on Thursday from new coronavirus vaccine news after just receiving a boost last week. The post OGEN Stock Alert: Why Oragenics Shares Are Flying Again ...

Business Wire - 2 days ago

TAMPA, Fla.--(BUSINESS WIRE)--Oragenics Issues Letter to Stockholders

InvestorPlace - 1 week ago

Oragenics (OGEN) is seeing shares of OGEN stock take off on Thursday on a news update for its vaccine to treat the novel coronavirus. The post OGEN Stock Alert: 14 Things to Know About Orageni...

Business Wire - 1 week ago

TAMPA, Fla.--(BUSINESS WIRE)--ORAGENICS ENTERS INTO MATERIAL TRANSFER AGREEMENT WITH ADJUVANCE TECHNOLOGIES FOR COVID-19 VACCINE ADJUVANT

Business Wire - 2 weeks ago

TAMPA, Fla.--(BUSINESS WIRE)--ORAGENICS ANNOUNCES CLOSING OF $6.5 MILLION REGISTERED DIRECT OFFERING

Business Wire - 3 weeks ago

TAMPA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. Announces $6.5 Million Registered Direct Offering

Business Wire - 1 month ago

TAMPA, Fla.--(BUSINESS WIRE)--Oragenics Announces Closing of $6.0 Million Underwritten Public Offering

Business Wire - 1 month ago

TAMPA, Fla.--(BUSINESS WIRE)--ORAGENICS PRICES $5.25 MILLION COMMON STOCK OFFERING

Business Wire - 1 month ago

TAMPA, Fla.--(BUSINESS WIRE)--Oragenics Announces Proposed Underwritten Public Offering

InvestorPlace - 3 months ago

Oragenics is planning to launch clinical trials of its coronavirus vaccine in early 2021. OGEN stock is soaring on the news.

Business Wire - 3 months ago

TAMPA, Fla.--(BUSINESS WIRE)--FDA Broadly Supports Oragenics’ Pre-IND Development Program for its SARS-CoV-2 Vaccine

Business Wire - 3 months ago

TAMPA, Fla.--(BUSINESS WIRE)--Oragenics Provides an Update on Funding for its SARS-CoV-2 Vaccine

Business Wire - 4 months ago

TAMPA, Fla.--(BUSINESS WIRE)--Oragenics Inc.

Business Wire - 4 months ago

TAMPA, Fla. & TUSTIN, Calif.

Business Wire - 5 months ago

TAMPA, Fla.--(BUSINESS WIRE)--Preclinical Study Shows SARS-CoV-2 Spike Protein Licensed by Oragenics from the NIH Produces Neutralizing Antibodies

About OGEN

Oragenics develops novel antibiotics against infectious diseases and treatments for oral mucositis. It is developing OG716, an antibiotic product candidate, which is in nonclinical testing for healthcare-associated infections, as well as other homolog antibiotic product candidates. The company is also developing AG013, which is in Phase II clinical trial for the treatment of oral mucositis in cancer patients. Its product candidates also comprise LPT3-04, a naturally occurring compound for use in weight loss; and SMaRT Replacement Therapy, a top... [Read more...]

Industry
Biotechnology
Founded
1996
CEO
Dr. Alan F. Joslyn
Employees
7
Stock Exchange
NYSEAMERICAN
Ticker Symbol
OGEN
Full Company Profile

Financial Performance

Financial Statements